Phibro Animal Health posts 27% sales growth; guides FY2026 net sales to $1.43B-$1.48B
Phibro Animal Health reported fiscal fourth-quarter and full-year results for the year ended June 30, 2025, with net sales of $1,296.2 million (up 27%) and net income of $48.3 million (up from $2.4 million). The company also issued fiscal 2026 guidance calling for net sales of $1.43 billion to $1.48 billion and net income of $73 million to $83 million, and the results and guidance were released in a press release furnished as Exhibit 99.1.
Key points
- Q4 net sales were $378.7 million, up 39%, and diluted EPS was $0.42 versus $0.02 a year earlier.
- Full-year diluted EPS was $1.19, up $1.13, and adjusted diluted EPS was $2.09, up 76%.
- FY2026 guidance includes adjusted EBITDA of $225 million to $235 million and diluted EPS of $1.79 to $2.03.
- Management said higher SG&A reflected investments in scaling operations, and gross leverage was 3.1x as of June 30, 2025.
The filing
Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.